Remove 2030 Remove Disease Remove Licensing
article thumbnail

Sentiment & Themes Emerging From JPM 2024

LifeSciVC

Naturally many of these acquisitions are driven by enthusiasm for clinical-stage assets that may contribute meaningfully to revenues in 2030+, and we are seeing Pharma build deeply in several key areas (obesity, immunology, oncology, neuro) as they add on to existing franchises or build new ones. Join the club. Additional trials (e.g.,

article thumbnail

BioArctic receives European patent for new antibodies targeting Alzheimer’s disease

The Pharma Data

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. STOCKHOLM , Jan. About BioArctic AB.

Disease 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Lilly’s donanemab receives U.S. FDA’s Breakthrough Therapy designation for treatment of Alzheimer’s disease

The Pharma Data

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). Dementia due to Alzheimer’s disease is the most common form of dementia, accounting for 60 to 80 percent of all cases 1.

article thumbnail

Identify and Validate Innovative Peptides for the Treatment of Obesity

The Pharma Data

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim. population will have obesity.

article thumbnail

Donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline

The Pharma Data

In the second, Lilly shared data showing that treatment with donanemab drives a rapid reduction of a biomarker reflecting Alzheimer’s disease pathology, plasma P-tau217, which was detected within 12 weeks. Lilly plans to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year.

Disease 52
article thumbnail

Bayer to launch Vynyty Citrus®, its newest biological product to control citrus farm pests during virtual symposium

The Pharma Data

It is licensed for commercial use by EcologĂ­a y ProtecciĂłn Agricola (EPA) in Valencia and provides 400 days of pest control. This biological solution responds to Bayer’s commitment to help reduce the environmental impact of crop protection by 30% by 2030 without reducing crop yields.

article thumbnail

Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries | Eli Lilly and Company

The Pharma Data

Lilly will donate both baricitinib (4 mg tablet) as well as bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together – providing options to treat COVID-19 patients at different stages of the disease. ” The allocation of therapies will be based on the disease burden and hospitalization rates in each country. .”